HeartBeam Stock Rockets 67.6% on FDA Review and Buy Ratings

Introduction

HeartBeam Inc. (NASDAQ: BEAT) is a Santa Clara, California-based medical technology company founded in 2015. The firm has developed a cable-free, credit-card-sized device that captures three-dimensional ECG signals and synthesizes them into a standard 12-lead ECG. HeartBeam holds over 20 issued patents and aims to enable actionable cardiac intelligence outside clinical settings, allowing physicians to monitor trends and acute conditions in various locations.

Corporate Structure

HeartBeam operates with a team of 11–50 employees and maintains its principal office at 2118 Walsh Avenue, Suite 210, Santa Clara, CA. The company’s investor relations are managed by MZ North America, and its transfer agent is VStock Transfer in Woodmere, New York. HeartBeam’s governance includes an executive leadership team supported by a board of directors experienced in medical devices, software development, and regulatory affairs.

ECG device by Marina Martynenko

Developments and News

• In December 2024, the U.S. Food and Drug Administration granted 510(k) clearance for HeartBeam’s 3D ECG technology to assess arrhythmias at home. Its 12-lead ECG synthesis software remains under FDA review.
• On November 13, 2025, HeartBeam conducted its Q3 2025 earnings call, with CEO Rob Eno and CFO Ti presenting operational updates and financial results.
• In November 2025, H.C. Wainwright & Co., LLC initiated coverage of BEAT with a Buy rating, highlighting the device’s synthesized ECG capability and estimating an initial market opportunity in concierge health care of $250 million to $500 million.
• Also in November 2025, ROTH Capital Partners began coverage with a Buy rating and set a $4.00 price target, citing the company’s positioning ahead of expected clearance for its 12-lead software.
• HeartBeam participated in the American Heart Association’s Scientific Sessions in November 2025, demonstrating its portable ECG system and engaging with clinicians and researchers.

Financial and Strategic Analysis

As of December 10, 2025, BEAT shares closed at $1.35, reflecting a 67.60% increase on a trading volume of 38,653,344 shares. Over the past 52 weeks, the stock has traded between $0.54 and $3.48. The company’s market capitalization is approximately $26.52 million, with an enterprise value of about $24.67 million.
For the trailing twelve months, HeartBeam reported a net income of negative $20.62 million, resulting in an earnings per share (EPS) of –$0.66. Total cash on the most recent balance sheet was $1.86 million, with levered free cash flow at –$7.7 million. HeartBeam carries no long-term debt. The price-to-book ratio is 65.32, reflecting a capital structure weighted toward intangible assets such as technology patents and software development.
Strategically, HeartBeam is positioned to transition from clinical feasibility to commercial rollout, with a limited product launch planned for 2026. FDA clearance of the 12-lead synthesis software is considered a key regulatory catalyst. The company’s patent portfolio supports potential partnerships with device manufacturers and remote-monitoring service providers.

Market Position and Industry Context

HeartBeam competes in the Healthcare Providers & Services sector, specifically in medical equipment manufacturing and digital health. Its synthesized 12-lead ECG device addresses gaps in ambulatory cardiac monitoring by combining portability with clinical-grade signal capture. While traditional Holter monitors and event recorders remain standard, HeartBeam’s platform targets a growing market for at-home diagnostics and telemedicine. Pending software clearance could expand its addressable market beyond concierge services to larger cardiology practices and remote care platforms.

tl;dr

On December 10, 2025, BEAT shares increased by 67.6% to $1.35 amid significant trading volume following analyst coverage by H.C. Wainwright and ROTH Capital. The company is awaiting FDA clearance for its 12-lead ECG synthesis software and plans a limited commercial launch in 2026. Key upcoming events include the conclusion of the software review and market rollout aimed at concierge and telehealth segments.